When Supply Chain Becomes a Clinical Choice: Governance, Predictability, and the Patient Divide

In this episode of Out of the Lab, host Nicholas Crudele sits down with repeat guests Carl, Hedley, and Angeliki to unpack the friction points across the cell and gene therapy supply chain. Moving beyond standard logistics, the panel explores why every supply chain decision is ultimately a clinical one, how operational unpredictability fuels physician referral hesitation, and why the disconnect between healthcare delivery and biomanufacturing systems must be bridged.Key Takeaways:Why a failed manufacturing run in autologous cell therapy represents a lost patient option rather than a simple shortage.The structural divide between hospital systems and biomanufacturing license holders.How supply chain unpredictability translates directly into clinical risk for physicians.The necessity of medical governance and the impact of patient starting material variability.Timestamps & Topics:00:00:00 – Introduction & Method Made Operational Intelligence00:01:36 – Logistical Friction Points & Human Handoffs in Autologous Therapies00:03:05 – The Structural Divide Between Healthcare Systems and Production00:04:26 – Every Supply Chain Decision as a Clinical Choice00:06:23 – Medical Governance and Decision-Making Authority00:11:37 – Integrating GMP & GDP Skills into Healthcare Settings00:18:37 – Starting Material as the Ultimate Manufacturing Wild Card00:21:25 – Physician Hesitation: Unpredictability vs. Efficacy00:23:08 – Cold Chain Realities and Wholesale Infrastructure Limits00:30:31 – Incremental Optimization vs. Rebuilding the Supply Chain

Despite rapid innovation in cell and gene therapy, clinical operational bottlenecks from severe workforce deficits to high geographic attrition continue to limit patient access.In this episode of Out of the Lab, host Nico Crudele sits down with Dr. Shernan Holtan, Chief of Blood and Marrow Transplantation and Professor of Medicine at Roswell Park Comprehensive Cancer Center. Dr. Holtan breaks down the workforce shortage facing cell therapy, the physiological reality of clinical decision fatigue, and why nearly 50% of referred CAR-T patients never receive treatment. She outlines practical operational solutions, including personalized clinical scheduling, predictive toxicity biomarkers (ferritin, CRP, physical mobility metrics), and Roswell Park's innovative Hub-and-Spoke shared care model designed to bring advanced therapies closer to community settings.Timestamps & Key Topics: 00:00:00 – Introduction & The Clinical Workforce Shortfall 00:05:00 – Why Medical Trainees Bypass Cell Therapy & BMT 00:08:48 – The 1,300 Physician Deficit & Post-Pandemic Burnout 00:15:43 – 400 Decisions a Day: Addressing Clinical Decision Fatigue 00:20:00 – The 50% Attrition Rate: Travel and Logistical Barriers in Rural Access 00:23:05 – Decentralizing Delivery: The "Hub-and-Spoke" Shared Care Model 00:28:03 – Standardizing Contingency Planning & The Role of APPs 00:31:31 – Operationalizing Predictability: Ferritin, CRP, and Physical Mobility Scoring

In this episode of Out of the Lab, host Nicholas Crudele sits down with Eytan Abraham, President, Minaris Viral Vectors. Together, they explore the emerging wave of in vivo lentiviral vectors (LVV) and the critical operational shifts required to move from personalized ex vivo CAR-T to off-the-shelf therapies.Ethan breaks down why traditional viral vector manufacturing faces severe yield losses during downstream purification, how early choices in cell lines and plasmids dictate final COGS, and why early-stage biotechs must begin with the "end game" in mind to ensure commercial reimbursement.Key Topics Covered:The In Vivo LVV Shift: Moving gene editing from outside the body (ex vivo) to inside the patient (in vivo).Tackling Upstream & Downstream Yield Losses: How producer cell lines and purification efficiencies lower cost per patient.The "End Game" Mindset: Why pricing, scale, and insurer reimbursement must be designed prior to Phase 1.Selecting the Right CDMO Partner: Questions founders must ask about tech transfer track records and platform leverage.Bridging Academic Silos: Educating PIs on translational manufacturing before locking in suboptimal processes.

In this episode of Out of the Lab, host Nicholas Crudele sits down with 20-year rare disease veteran Chad to dissect the operational hurdles of commercializing specialized therapies globally.Traditional big pharma launch models rely on heavy local infrastructure and massive fixed overhead: a formula that creates unsustainable burn rates for biotechs targeting ultra-rare patient populations. Chad outlines how emerging biotechs can maintain strategic control, navigate complex APAC market access dynamics, and launch efficiently using lean operational frameworks.Key Topics Discussed:The Infrastructure Gap: Why traditional local-affiliate expansion models burn cash too quickly in ultra-rare diseases.The 4S Launch Model: Building commercial setups that are Smaller, Specialized, Speed-driven, and Sustainable.The Virtual Subsidiary Approach: How to rent local execution infrastructure without relinquishing strategic control to third-party distributors.Navigating APAC Market Access: Utilizing pragmatic pricing strategies and confidential risk-sharing deals in South Korea to protect global reference pricing.Network Orchestration: Governing external partner networks with a unified launch master plan to avoid fragmented execution.Timestamps:00:00:00 – Introduction & Method Made Operational Intelligence00:01:04 – Chad's Background in Rare Disease Commercialization00:02:24 – The Heavy Infrastructure Gap in Traditional Pharma Launches00:04:15 – Breaking Down the 4S Launch Framework00:05:48 – Virtual Subsidiaries vs. Distributor Trade-Offs00:09:05 – Execution Friction & Market Access in APAC / South Korea00:11:08 – When to Align Global Reimbursement Strategies00:12:43 – Orchestrating Partner Networks & Governing Execution00:15:35 – Sustainable Operations & Long-Term Patient Access

While commercial cell and gene therapies are transforming medicine, academic medical centers face a massive, operational burden when delivering them. From juggling separate vendor software portals to guiding lost couriers carrying $3M therapies through hospital corridors, point-of-care delivery is fraught with administrative and physical friction.In this episode of Out of the Lab, host Nico Crudele sits down with Dr. Patrick Hanley, Director of Cellular Therapy at Children's National Hospital. Together, they break down the real-world disconnects between commercial biopharma developers, hospital stem cell labs, and final patient delivery.Key Topics Discussed:Portal Fatigue: Why custom vendor portals, IT approvals, and unique qualification forms create immense administrative overhead for hospital staff.The Hospital Shipping Strain: How commercial manufacturing delays and re-collections caused a hospital cell lab's shipment volume to explode from near zero to 90+ shipments annually.Tacit Knowledge in Tech Transfer: How terms like "gently resuspend" or "ice-cold PBS" lead to cracked flasks, variable yields, and batch failures.Decentralized Manufacturing & Regulatory Pathways: Exploring rapid BLA mechanisms and point-of-care models for rare pediatric diseases.Training Beyond Hardware: Why the industry over-indexes on equipment training while ignoring essential quality soft skills like deviation writing and root-cause analysis.Brought to you by Method Made. Accelerate your tech transfer by up to six months using video SOPs to capture technical nuance. Download the free Tech Transfer Failure Modes and Effects Analysis at methodmade.ca.

 In this episode of Out of the Lab, host Nico Crudele sits down with Michelle Hill, a 30-year biotech veteran, Kite Gilead alum and founder of Avenue to Care, to examine why revolutionary cell therapies like CAR T are failing to reach over 80% of eligible patients.Michelle breaks down the severe non-clinical, operational, and socioeconomic barriers keeping advanced treatments locked behind elite academic medical centers. From community physician referral gaps and geographic attrition to building data-neutral care orchestration platforms, this conversation explores how the industry can bridge the gap between treatment availability and true patient access.Key Takeaways:Why CAR T adoption has plateaued at 20% and how current access disproportionately favors patients with health literacy and financial means.How general oncologists' lack of familiarity with cell therapy risks and successes creates early patient drop-outs.The role of non-clinical care orchestration in restoring patient agency without crossing pharma compliance boundaries.Navigating post-treatment survivorship, long-term follow-up registry demands (CIBMTR), and the impact of REMS updates on patient travel requirements.Timestamps & Key Topics:00:00:00 – Introduction & Method Made Sponsor00:01:16 – The 80% Access Deficit & Infrastructure Gaps00:03:32 – The 10-Mile Rule & Geographic Attrition00:06:26 – Early Diagnoses & The Loss of Patient Agency00:11:32 – Rare Disease, Autoimmune, and the CAR T Horizon00:14:07 – General Oncologist Referral Hesitancy & Perceived Failures00:17:03 – Socioeconomic Privilege in Clinical Access00:22:17 – Introducing Avenue to Care: Public Benefit Care Orchestration00:26:34 – Post-Treatment Care, Survivorship, & Long-Term Data Tracking00:31:07 – Global Access Challenges & Health Literacy00:35:12 – Rebuilding Healthcare Around the Patient

Why do processes that look clean on paper collapse during an FDA inspection?In this episode of Out of the Lab, host Nico Crudele sits down with ex-FDA auditors DeVaughn Edwards (GMP specialist) and Elvia Cervantes (GCP specialist) to break down the most common and preventable compliance disasters in cell and gene therapy.From night-shift compliance breakdowns and paper-only CDMO audits to data manipulation and informal quality decisions, DeVaughn and Elvia share unvarnished insights from their time inside the agency and in the field.Key Takeaways:You Can't Outsource Liability: Why delegating manufacturing to a CDMO or clinical monitoring to a CRO does not clear a sponsor's regulatory responsibility.The "Boots on the Ground" Mandate: Why paper questionnaires fail vendor qualification and how unmonitored night shifts breed compliance failures.Building Code vs. Blueprint: The cost of bringing Quality teams in midstream rather than from project inception.Data Integrity Realities: What actual record destruction and email-based decision-making signal to FDA investigators.Modern Audit Readiness: How remote regulatory assessments (RRAs), 1-day audits, and AI tools like ELSA are changing FDA oversight.Timestamps / Show Notes:00:01:16 – The cost of involving Quality teams too late in development.00:05:29 – Qualifying CDMOs: Why "boots on the ground" beat paper questionnaires.00:09:08 – The 2 AM reality check: Night shift compliance breakdowns.00:14:00 – Modern audit readiness, 1-day inspections, and FDA’s ELSA system.00:24:43 – Data integrity red flags: Document destruction and pressure-driven cover-ups.00:41:33 – Operational silos: When administrative assistants make escalation decisions.00:47:32 – What an effective CAPA actually looks like.01:05:15 – Inspecting emails and server migrations as regulatory liabilities.

Why does selecting the cheapest CDMO quote often lead to millions of dollars in unexpected costs down the road?In this episode of Out of the Lab, host Nico sits down with industry veteran Shri Joshi, who has navigated cell and gene therapy operations across consulting, CDMO, and sponsor sides to break down the core ingredients of a successful drug development lifecycle.We explore why CDMO selection must be treated as a development and risk-management decision rather than a simple procurement task. Shri breaks down why early investments in analytical methods create crucial operational flexibility, why the adage "the process is the product" can actually harm development, and how early-stage founders can build a true "comparability mindset" to de-risk clinical progression.Key Topics Covered:00:01:34 – The 3 core ingredients of cell & gene therapy development00:04:20 – Why CDMO selection is a risk management decision, not procurement00:07:28 – Case Study: Transparency vs. unrealistic timeline promises00:18:38 – The real cost of cheap contracts: How a $1M discount cost $5M later00:21:41 – CMC 101: Chemistry, Manufacturing, & Controls explained00:24:37 – Why "the process is the product" dogma creates operational bottlenecks00:27:53 – Developing analytical methods early to enable comparability00:32:04 – Utilizing Quality Target Product Profiles (QTPP) & Process Flow DiagramsThis episode is brought to you by Method Made. Accelerate your tech transfer by up to six months using video SOPs to capture technical nuance. Download the free Tech Transfer Failure Modes and Effects Analysis at methodmade.ca by clicking Download FMEA.

Why do brilliant R&D processes stall or fail when transferred into a GMP cleanroom?In this episode of Out of the Lab, host Nicholas Crudele sits down with Jerry from CellBri to unpack the unspoken assumptions, technical miscommunications, and equipment hurdles that delay cell therapy manufacturing. From the reality of using ice buckets instead of precise 4°C incubation to reducing batch COGS from $150,000 down to under $20,000 using flexible automation, Jerry breaks down how effective communication through documentation and smart software UX de-risk cell therapy scale-up.Key Topics Covered:The R&D vs. Cleanroom Disconnect: Why gowning, double-gloving, and workflow timing ruin unexamined bench protocols during tech transfer.The "Oral Tradition" Trap: How minor miscommunications (0°C vs. 4°C) can cause month-long troubleshooting investigations.Slashing COGS with Flexible Automation: How modern automated systems dramatically cut labor costs and production days.UX in the Cleanroom: Replacing ambiguous error codes with on-screen video guidance to prevent catastrophic batch losses.

Is manufacturing complexity really the main bottleneck holding back cell and gene therapies, or are we ignoring the operational friction occurring right at the physician's desk?In this episode of Out of the Lab, host Nicholas Crudele sits down with Carl Schoellhammer, Partner at DeciBio, to discuss why the cell therapy industry must shift its focus from cleanroom COGS to physician awareness, simplified prescribing workflows, and clinical adoption.Carl shares his perspective on the barriers stalling patient access, comparing centralized US logistics with Europe’s decentralized hospital exemption framework and explaining why the key to scaling cell therapies lies in streamlining the entire prescribing journey.Key Takeaways:The Manufacturing Fallacy: Why COGS and production complexity are no longer the primary bottlenecks limiting cell therapy scale.Portal Fatigue: How fragmented drug scheduling systems force doctors to hunt for passwords on Post-it notes just to write a script.The European Exemption Model: How centers like Hospital Clínic de Barcelona are leveraging hospital exemption acts to dose over 500 patients in-house.Solving Logistics: Easing the administrative and travel burdens on non-metropolitan patients.Predictive Operations: How automated analytics and process monitoring can drastically lower batch failure rates.